Board of Directors
Mr. DeLuccia is co-founder of our company, and currently serves as Executive Chairman and as a director. From January 2010 to March 2014, Mr. DeLuccia served as co-founder and Managing Partner of our Company. From 2004 to 2009 Mr. DeLuccia served in several capacities at MacroChem, a development-stage, publicly traded pharmaceutical company using topical drug delivery technology for products in dermatology, podiatry, urology and cancer, including roles as Chairman, President and Chief Executive Officer, and as director. Mr. DeLuccia also has served as President and Chief Executive Officer of Immunomedics, Inc., a publicly-traded biopharmaceutical company focused on antibody-based therapeutic products and diagnostic imaging for cancer and infectious diseases and as President of Sterling Winthrop, Inc. (or Sterling Winthrop) (as an independent corporation and then as subsidiary of Eastman Kodak), and subsequently, upon acquisition, the U.S. subsidiary of Sanofi-Aventis (or Sanofi). Mr. DeLuccia currently serves as a member of the board of directors of IBEX Technologies Inc. (TSX Venture Exchange: IBT), a Canadian biopharmaceutical company engaged in the production and sale of proprietary enzymes for use as reagents for hemostasis monitoring devices. Mr. DeLuccia began his career as a pharmaceutical sales representative for Pfizer, Inc. (or Pfizer) and progressed to Director of Marketing, Pfizer Laboratories Division and to Vice President Marketing and Sales Operations for Pfizer's Roerig Division. Mr. DeLuccia received a Bachelor of Business Administration with a concentration in Marketing and a Master's Degree in Business Administration, both from Iona College.
Mr. Luci co-founded Dipexium Pharmaceuticals and currently serves as President & Chief Executive Officer and is a member of the board of directors. Prior to co-founding Dipexium Pharmaceuticals, from 2007 to January 2010, Mr. Luci served as a member of the board of directors of Access Pharmaceuticals, Inc., where he also served as Chairman of the Audit Committee and Chairman of the Compensation Committee as well as serving in a consulting capacity following the acquisition of MacroChem Corporation. From December 2007 through February 2009, Mr. Luci also served as a member of the board of directors and in several management capacities of MacroChem, including President, Chief Financial Officer and General Counsel. Prior to that, Mr. Luci served as Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary of Bioenvision, Inc., an international biopharmaceutical company engaged in the development, marketing and commercialization of oncology products. Mr. Luci created and managed Bioenvision's principal executive offices located in New York, New York as well as its satellite office located in Tokyo, Japan. Mr. Luci was instrumental in creating Bioenvision's international commercial enterprise; managed the worldwide development of Evoltra (clofarabine) as a member of the product's Joint Steering Committee in with senior executives of Genzyme Corporation; and orchestrated, structured and negotiated the sale of Bioenvision to Genzyme for $345 million in 2007. Mr. Luci began his career with Ernst & Whinney LLP (now Ernst &Young LLP) in New York as a certified public accountant working in the Healthcare Practice Group. He later practiced corporate law at Paul Hastings LLP in New York for eight years, where his practice encompassed all aspects of public and private mergers and acquisitions, contract negotiations, corporate finance, restructurings and private equity transactions, with a core focus in the healthcare indust ry. Mr. Luci graduated from Bucknell University with a degree as a Bachelor of Science in Business Administration with a concentration in Accounting and graduated with honors from Albany Law School of Union University where he served as Managing Editor of the Journal of Science & Technology. Mr. Luci became a certified public accountant in the State of Pennsylvania in 1990 (inactive) and is a member of the New York State Bar Association.
Mr. McSherry has served as a director of our company since October 2010. Mr. McSherry has served as a partner at Eaton & Van Winkle LLP in New York since 2014 in the firm's litigation department, where he specializes in the areas of securities, mergers and acquisitions, financial institutions, derivatives, structured finance, insurance, reinsurance, life sciences, real estate, product liability and trademark law. Mr. McSherry previously served as a partner and the New York Chair of Crowell & Moring's Litigation Group from 2006 to 2014, during which he conducted numerous trials and arbitrations throughout the U.S. Prior to joining Crowell & Moring LLP, Mr. McSherry served as a partner at Arent Fox LLP in New York from 2000 to 2006. Mr. McSherry received his B.A. from Fordham College in 1969 and received a J.D. from Harvard Law School in 1973. Mr. McSherry is an active member of the American Bar Association, the New York State Bar Association, the U.S. Supreme Court Historical Society and the Association of the Bar of the City of New York, where he also served as a member of several committees: State Courts of Superior Jurisdiction (from 1980 to 1983), Arbitration and ADR (from 1987 to 1989) and Sports Law (from 1999 to 2001). Mr. McSherry is also a member of the New York State Bar Association. Mr. McSherry has published articles on numerous litigation related topics as well as a chapter on derivatives litigation in a publication entitled "Derivatives and Risk Management."
Dr. Dean has served as a director of our company since October 2010. Since 2006, Dr. Dean has served as Professor in the Department of Pharmacology and Toxicology, Collage of Pharmacy, at the University of Arizona, Tuscon and as President of Drug Development Advisors, LLC, where he consults with pharmaceutical companies on drug safety issues, drug development, regulatory strategy and immunotoxicology.
Prior to 2006, Dr. Dean served as President, U.S. Science and Medical Affairs, for Sanofi-Aventis, and as Global Director of Preclinical Development for Sanofi-Aventis. During his 18 year tenure at Sanofi-Aventis and legacy companies, he was involved with the registration of eight New Drug Applications (NDAs) for the US and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin. Prior to Sanofi-Aventis, he headed the Department of Cellular and Molecular Toxicology, Chemical Industry Institute of Toxicology, from 1982-1988. Prior to 1982, he headed the Immunotoxicology Section, National Institute of Environmental Health Services and National Toxicology Program, National Institutes of Health. Prior to NIH, Dr. Dean served as Director, Department of Immunology at Litton Bionetics, conducting research in tumor immunology.
Dr. Dean holds a B.S. in microbiology and an M.S. in medical microbiology from California State University, Long Beach. He earned a Ph.D. in molecular biology and minor in biochemistry (1972) from the College of Medicine, University of Arizona. Dr. Dean held adjunct professorships at the University of North Carolina, Chapel Hill and Duke University (1981-1988). He has edited seven books and published over 230 journal articles and book chapters. He was the first recipient of the Lifetime Career Achievement Award by the Immunotoxicology Specialty Section of the Society of Toxicology (2000) and a recipient of the American College of Toxicology’s “Distinguished Service Award” in 2003. In 2005, the College of Pharmacy at the University of Arizona bestowed upon him an honorary Doctor of Science degree. On September 12th, 2006 in Paris, the French Republic bestowed upon him “Chevalier” of the Legion of Honor, an award given for his “contribution to medical and pharmaceutical research.
Mr. Harrison has served as a director of our company since November 2012. He has worked at the Omnicom Group since 1992 and currently serves as Chairman (Emeritus) of Diversified Agency Services, a division of the Omnicom Group. Prior to joining the Omnicom Group by acquisition of his company in 1992, Mr. Harrison was the founder and Chairman of the Harrison & Star Group, a healthcare Public Relations company, a Medical Education company, and healthcare Direct-to-Consumer advertising agency. Mr. Harrison began his career in 1974 as a pharmaceutical sales representative at Pfizer before continuing on to found and/or manage several healthcare advertising agencies. Currently, Mr. Harrison is a member of the Executive Committee of the Montefiore Health System, New York, and is a Fellow of the New York Academy of Medicine. He also currently serves as a Chairman of the Audit Committee of Fifth Street Asset Management and a Governor of the New York Academy of Sciences. He previously served as a Board Member of ePocrates, Inc., a healthcare information company, Morgans Hotel Group, and the New York Chapter of the Arthritis Foundation. Mr. Harrison holds advanced degrees in biology and physiology earning a graduate degree from West Virginia University in 1972 and an Honorary Doctorate from West Virginia University in 2007.
Mr. Duffy has served as a director of our company since February 2013. Mr. Duffy currently serves as the managing partner of the law firm, Duffy & Duffy, PLLC, is a highly experienced civil litigator with a passion for the law and a desire to represent victims of medical malpractice, where he has practiced since 1996. Mr. Duffy concentrates his practice on catastrophically injured victims and wrongful death claims involving medical malpractice and personal injury. Throughout his career, Mr. Duffy has been repeatedly named in Best Lawyers in America. Mr. Duffy received a J.D. from St. John's University and a Bachelor of Science degree in Business Administration from St. John's University. Mr. Duffy was admitted to the New York State Bar in 1995.
Mr. Kagan has served as a director of our company since July 2014. Mr. Kagan is the founder of MBL Barry Corp. (“MBK”), a consulting firm which provides emerging and existing hedge fund managers with advice on infrastructure, launching of new products, tax and accounting issues. From July 2012 to December 2013 Mr. Kagan was also a director of the Company. Prior to forming MBL in July 2013, Mr. Kagan joined CBM Capital Inc. (“CBM”), a New York based registered investment advisory firm, in 2007 where he served as Executive Officer of Financial Operations. While at CBM, Mr. Kagan was responsible for all financial, accounting, legal and compliance functions for domestic and offshore funds. From 2003 to 2007, Mr. Kagan was the Chief Financial Officer of Bedford Oak Advisors, LLC (“Bedford”), a New York based investment advisory firm whose clients comprised primarily high net worth individuals and institutions. While at Bedford, Mr. Kagan was responsible for all financial, accounting, legal, compliance and estate planning functions. In addition, Mr. Kagan held various similar positions at various companies within the financial services sector since his graduation. Mr. Kagan received a Bachelor of Business Administration degree Magna cum laude from Hofstra University School of Business in 1980.